Pharmaceutical News

RSS

Denosumab increases bone density for postmenopausal women with osteoporosis

Postmenopausal women with osteoporosis who take denosumab long-term have increased bone density, sustained low rate of fractures, and a favorable benefit/risk profile, a new multinational study finds.

23 Jun 2014

African American women respond differently to anti-inflammatory effect of aspirin than white women

African American women respond differently to the anti-inflammatory effect of aspirin than do white American women, new research finds.

23 Jun 2014

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration approved SIVEXTRO (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI).

21 Jun 2014

Continuation of metformin after cirrhosis diagnosis improves survival rates in diabetes patients

Researchers at Mayo Clinic released a new study reversing current thought on the treatment of cirrhotic patients with type 2 diabetes.

20 Jun 2014

Arthritis drug promotes hair growth in hairless man

A man with almost no hair on his body has grown a full head of it after a novel treatment by doctors at Yale University.

20 Jun 2014

Review on effects of treating cholera with antimicrobial drugs

Researchers from the Cochrane Infectious Diseases Group, co-ordinated through the editorial base in LSTM, conducted an independent review of the effects of treating cholera with antimicrobial drugs, published in The Cochrane Library today.

19 Jun 2014

Apitope starts preclinical development of ATX-GD-459 for Graves' disease treatment

Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that it has started preclinical development of its novel peptide therapy ATX-GD-459 for the treatment of Graves' disease.

19 Jun 2014

Takeda decides to terminate development of orteronel for prostate cancer

Takeda Pharmaceutical Company Limited announced today that it has voluntarily decided to end the development program for orteronel (TAK-700) for prostate cancer. The decision follows the results of two Phase 3 clinical trials in metastatic, castration resistant prostate cancer (mCRPC).

19 Jun 2014

Medison to market uniQure's Glybera in Israel for treatment of lipoprotein lipase deficiency

uniQure N.V., a leader in human gene therapy, and Medison Pharma Ltd., Israel's leading international healthcare marketing group, today announced an exclusive distribution agreement under which Medison will market Glybera, uniQure's gene therapy product for the treatment of lipoprotein lipase deficiency (LPLD), in Israel and the Palestinian Authority.

18 Jun 2014

IGI Laboratories submits third ANDA in 2014 to FDA

IGI Laboratories, Inc., a New Jersey based generic topical pharmaceutical company, today announced it has submitted its third abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration, which brings the Company's total number of ANDA submissions to sixteen, with fourteen now pending at the FDA.

18 Jun 2014

Janssen signs license agreement with Vertex to develop, commercialize VX-787 for influenza A treatment

Janssen Pharmaceuticals, Inc.announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing and commercialization of VX-787, a novel medicine in Phase II development for the treatment of influenza A.

18 Jun 2014

New strategy for treating neuroblastoma using modified version of heparin

Researchers at Duke Medicine have identified a new strategy for treating neuroblastoma using a modified version of heparin, a century-old injectable drug that thins the blood to prevent clots from forming.

18 Jun 2014

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with Selecta Biosciences for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis.

18 Jun 2014

Clot-busting medications for treating pulmonary embolism patients linked with fewer deaths

Bringing clarity to a decades-long debate, a national team of researchers led by experts from the Perelman School of Medicine at the University of Pennsylvania has found that adding clot-busting medications known as thrombolytics to conventional approaches when treating sudden-onset pulmonary embolism patients is associated with 47 percent fewer deaths than using standard intravenous or under-the-skin anticoagulant medications alone.

18 Jun 2014

FDA accepts Symplmed's Prestalia NDA for hypertension treatment

Symplmed announced today that the U.S. Food and Drug Administration has accepted for review its New Drug Application (NDA) for investigational drug Prestalia, the first single-pill, fixed-dose combination (FDC) of perindopril arginine and amlodipine besylate for the treatment of hypertension in the U.S. Symplmed filed the application under section 505(b)(2) consistent with FDA's guidance.

18 Jun 2014

Study compares effectiveness of selumetinib, chemotherapy in patients with advanced uveal melanoma

In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival, according to a study in the June 18 issue of JAMA. The modest improvement in clinical outcomes was accompanied by a high rate of adverse events.

18 Jun 2014

Hypertension medication may cause metabolic-related adverse events in older adults

Adults over 65 who have recently begun thiazide diuretics are at a greater risk for developing metabolic-related adverse events, researchers at UT-Southwestern Medical Center have found.

18 Jun 2014

Researchers find sharp increase in deaths from commonly prescribed painkillers in US, Canada

The number of deaths involving commonly prescribed painkillers is higher than the number of deaths by overdose from heroin and cocaine combined, according to researchers at McGill University.

18 Jun 2014

Single dose restores normal cellular signaling in mouse model of autism

In a further test of a novel theory that suggests autism is the consequence of abnormal cell communication, researchers at the University of California, San Diego School of Medicine report that an almost century-old drug approved for treating sleeping sickness also restores normal cellular signaling in a mouse model of autism, reversing symptoms of the neurological disorder in animals that were the human biological age equivalent of 30 years old.

18 Jun 2014

BIPI, Lilly announce resubmission of empagliflozin NDA to FDA for treatment of type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the resubmission of a New Drug Application (NDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin for the treatment of adults with type 2 diabetes (T2D) to the U.S. Food and Drug Administration (FDA).

17 Jun 2014

Pharmaceutical News

Denosumab increases bone density for postmenopausal women with osteoporosis

African American women respond differently to anti-inflammatory effect of aspirin than white women

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Continuation of metformin after cirrhosis diagnosis improves survival rates in diabetes patients

Arthritis drug promotes hair growth in hairless man

Review on effects of treating cholera with antimicrobial drugs

Apitope starts preclinical development of ATX-GD-459 for Graves' disease treatment

Takeda decides to terminate development of orteronel for prostate cancer

Medison to market uniQure's Glybera in Israel for treatment of lipoprotein lipase deficiency

IGI Laboratories submits third ANDA in 2014 to FDA

Janssen signs license agreement with Vertex to develop, commercialize VX-787 for influenza A treatment

New strategy for treating neuroblastoma using modified version of heparin

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

Clot-busting medications for treating pulmonary embolism patients linked with fewer deaths

FDA accepts Symplmed's Prestalia NDA for hypertension treatment

Study compares effectiveness of selumetinib, chemotherapy in patients with advanced uveal melanoma

Hypertension medication may cause metabolic-related adverse events in older adults

Researchers find sharp increase in deaths from commonly prescribed painkillers in US, Canada

Single dose restores normal cellular signaling in mouse model of autism

BIPI, Lilly announce resubmission of empagliflozin NDA to FDA for treatment of type 2 diabetes

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News